Abstracts Archive - Page 773 of 1683 - ATC Abstracts

2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
M. Gastaca,¹ J. Bustamante,² A. Ventoso,¹ J. Fernandez,² P. Ruiz,¹ M. Testillano,² M. Prieto,¹ P. Salvador,² I. Palomares,¹ M. Senosiain,² M. Suarez,² A. Valdivieso.¹
¹Hepatobiliary Surgery and Liver Transplant Unit, Cruces University Hospital, Bilbao, Spain; ²Hepatology Unit, Cruces University Hospital, Bilbao, Spain.
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…
2018 American Transplant Congress
De Novo Use of Extended Released Tacrolimus (Meltdose, Envasus^R)) after OLT – Does the Colonic Resorption Influences the Outcome?
T. Soliman, G. Györi, M. Hofmann, A. Salat, S. Rockenschaub, G. Berlakovich.
Department of Transplantation, Medical University of Vienna, Vienna, Austria.
Introduction: Immunosuppression after OLT has reached a quite high standard with an excellent evidence base. However, there is still a lack of data for the…
2018 American Transplant Congress
The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
M. Del Gaudio,¹ M. Cescon,¹ M. Ravaioli,¹ V. Bertuzzo,¹ C. Zanfi,¹ M. Serenari,¹ L. Maroni,¹ C. Morelli,² A. Pinna.¹
¹Organ Insufficiency and Transplantation, S.Orsola Hospital General Surgery and Transplantation Unit Prof. A.D. Pinna, Bologna, Italy; ²Organ Insufficiency and Transplantation, S. Orsola Hospital Organ Insufficiency and Internal Medicine Morelli, Bologna, Italy.
The safety and efficacy of substitution with a novel once-daily extended-release tacrolimus (LCPT;Envarsus®)to immediate-release tacrolimus (IR-Tac, Prograf®) twice daily in liver transplant patients have not…
2018 American Transplant Congress
Effects of the Addition of Mycophenolate Mofetil on Renal Outcomes in Liver Transplant Recipients: A Single Center Review
M. Henry, M. Vacha.
Nebraska Medicine, Omaha, NE.
Purpose: To evaluate the use of mycophenolate mofetil (MMF) and its effects on renal outcomes in liver transplant recipientsMethods: Adult liver transplant recipients from September…
2018 American Transplant Congress
Side Effect Profile of Everolimus in Liver Transplant Patients
F. Kumssa, O. Sadiq, M. Alimirah, R. Kaur, A. Patel, S-.M. Jafri.
Henry Ford Hospital, Detroit.
IntroductionUse of calcineurin inhibitors has been the mainstay of antirejection medications after liver transplant (LT). However, renal toxicity from these drugs remains troublesome. By comparison,…
2018 American Transplant Congress
Rituximab Induction to Prevent the Recurrence of PSC after Liver Transplantation-The Lessons Learned from ABO-Incompatible Living Donor Liver Transplantation-
Y. Yamada,¹ K. Hoshino,¹ M. Shinoda,¹ H. Obara,¹ S. Uemoto,³ T. Kaido,³ H. Okajima,³ T. Yagi,⁴ T. Yoshizumi,⁵ Y. Inomata,⁶ T. Hibi,⁶ K. Kubota,⁷ T. Suzuki,⁸ Y. Kitagawa,¹ H. Egawa,² T. Kuroda.¹
¹Surgery, Keio University School of Medicine, Tokyo, Japan; ²Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan; ³Division of Hepato-Biliary-Pancreatic Surgery and Transplant Surgery, Kyoto University, Kyoto, Japan; ⁴Hepato-Biliary and Pancreatic Surgery, Okayama University, Okayama, Japan; ⁵Department of Surgery, Kyushu University, Fukuoka, Japan; ⁶Transplantation and Pediatric Surgery, Kumamoto University, Kumamoto, Japan; ⁷Department of Gastroenterological Surgery, Dokkyo Medical University, Tochigi, Japan; ⁸Department of Pediatric Surgery, Fujita Health University School of Medicine, Aichi, Japan.
Background: Multiple studies have failed to reveal an effective method for preventing the recurrence of primary sclerosing cholangitis (PSC) after liver transplantation (LTx). A national…
2018 American Transplant Congress
Single Center Experience of HLA-Related Donor Specific Antibody in Living Donor Liver Transplantation
H. Egawa,¹ Y. Kotera,¹ A. Ohmori,¹ S. Yamashita,¹ T. Kato,¹ S. Nemoto,¹ T. Ishizuka,² M. Yamamoto.¹
¹Surgery, Tokyo Women's Medical University, Tokyo, Japan; ²Clinical Laboratory, Tokyo Women's Medical University, Tokyo, Japan.
Although impact of donor specific antibody in liver transplantation has been recognized, significance of desensitization is not established yet. Our aim is to share our…
2018 American Transplant Congress
The Efficacy of Low Dose Steroid Therapy for Postoperative Hyperbilirubinemia in Liver Transplant Recipients: A Prospective Randomized Controlled Trial
J. Yang, X. He, L. Wu, Z. Guo.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Background: Hyperbilirubinemia is a common but reversible event after liver transplantation . Steroids is a widely used anti-inflammatory agent, which may help improve allograft function,…
2018 American Transplant Congress
The Net State of Immunosuppression in Septuagenarian Liver Transplant Recipients: Balancing Rejection and Infection Risks
J. Casale,¹ J. Clark,¹ B. Ravichandran,¹ J. LaMattina.²
¹Pharmacy, University of Maryland Medical Center, Baltimore; ²University of Maryland School of Medicine, Baltimore.
Purpose: Careful patient selection and perioperative management have allowed for successful liver transplantation in elderly patients. Elderly patients may be more susceptible to the infectious…
2018 American Transplant Congress
Adjunctive Corticosteroid Immunosuppression Improves Hyperbilirubinemia Following Liver Transplantation (OLT)
G. Malat, D. Reich, G. Xiao, M. Harhay, K. Ranganna, D. Lee, S. Guy, S. Munoz.
Drexel University, Philadelphia.
Background: Deceased donor orthotopic liver transplantation (OLT) can result in significant delayed function, manifesting as protracted hyperbilirubinemia, depending on the intensity of the ischemia/reperfusion injury…